Refocusing cancer R&D for greater impact: Addressing gaps in disparities and access

Trodelvy + Keytruda show potential as new standard of care in first-line PD-L1+ metastatic TNBC, phase III trial finds

Patients saw a 35% reduced risk of disease progression or death for Trodelvy (sacituzumab govitecan-hziy) plus Keytruda (pembrolizumab) (n=221) versus standard of care Keytruda plus chemotherapy (n=222), according to the positive phase III ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy plus Keytruda in first-line PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer.

January 23, 2026

Vol.52 No.03

Podcast

With five-year cancer survival at an all-time high, does this mean people are living longer?

“It's really, really important that every year since 1991, cancer mortality has dropped by a little bit, and it did again!” said Paul Goldberg, editor and publisher of The Cancer Letter. “Now, mortality is a good metric, age-adjusted mortality. As far as survival, well, that's not so good.”

January 21, 2026

Clinical News Analysis

ACS report trumpets 70% five-year survival for all cancers amid uncertain funding outlook

The American Cancer Society’s 2026 annual statistics report trumpets a symbolic milestone for oncology—for the first time, the five-year relative survival rate for all cancers combined has reached 70% for people diagnosed between 2015 and 2021 in the U.S.

January 16, 2026

Vol.52 No.02

By Jacquelyn Cobb and Paul Goldberg

In Brief

SU2C + CRUK secure $3M for gastric cancer research

Stand Up To Cancer and Cancer Research UK secured $3 million in new support for a “dream team” focused on stopping gastric cancer in its earliest stages.

January 16, 2026

Vol.52 No.02

Drugs & Targets

Verana Health and COTA merge to accelerate research-ready oncology real-world evidence

Verana Health and COTA Inc. are merging with the aim of providing data and software solutions for real-world insights that accelerate clinical research, expedite treatment options, and improve patient care.

January 16, 2026

Vol.52 No.02

Cancer Policy

Journal retracts decades-old study that determined glyphosate, widely used herbicide, as safe

Regulatory Toxicology and Pharmacology has retracted a literature review published in 2000 that concluded that glyphosate, a common herbicide used in agriculture and found in products such as Roundup, “does not pose a health risk to humans.”

January 09, 2026

Vol.52 No.1

By Sara Willa Ernst

Refocusing cancer R&D for greater impact: Addressing gaps in disparities and access

YOU MAY BE INTERESTED IN

Trodelvy + Keytruda show potential as new standard of care in first-line PD-L1+ metastatic TNBC, phase III trial finds

With five-year cancer survival at an all-time high, does this mean people are living longer?

ACS report trumpets 70% five-year survival for all cancers amid uncertain funding outlook

SU2C + CRUK secure $3M for gastric cancer research

Verana Health and COTA merge to accelerate research-ready oncology real-world evidence

Journal retracts decades-old study that determined glyphosate, widely used herbicide, as safe

Renew today!

Subscriber content

Never miss an issue!

Login